{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:18:35Z","timestamp":1792001915406,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":60,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.lungcan.2025.108554","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T11:15:18Z","timestamp":1745925318000},"page":"108554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Therapeutic management of patients with advanced thymic malignancies: A review for clinicians"],"prefix":"10.1016","volume":"204","author":[{"given":"Valeria","family":"Pavese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica Maria","family":"Carf\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Capelletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Tabb\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passiglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisella","family":"Righi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Novello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Merlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bironzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2025.108554_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102014","article-title":"Thymic epithelial tumors: From biology to treatment","volume":"86","author":"Conforti","year":"2020","journal-title":"Cancer Treat. Rev."},{"issue":"36","key":"10.1016\/j.lungcan.2025.108554_b0010","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1200\/JCO.2011.36.0487","article-title":"Thymic malignancies: from clinical management to targeted therapies","volume":"29","author":"Kelly","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2025.108554_b0015","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1111\/1759-7714.13181","article-title":"Optimal first-line treatment for advanced thymic carcinoma","volume":"10","author":"Yang","year":"2019","journal-title":"Thorac. Cancer"},{"issue":"167","key":"10.1016\/j.lungcan.2025.108554_b0020","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0174-2022","article-title":"Rare thoracic cancers: a comprehensive overview of diagnosis and management of small cell lung cancer, malignant pleural mesothelioma and thymic epithelial tumours","volume":"32","author":"Dumoulin","year":"2023","journal-title":"Eur. Respir. Rev."},{"key":"10.1016\/j.lungcan.2025.108554_b0025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.21037\/med-21-11","article-title":"Systemic treatments for thymic tumors: a narrative review","volume":"5","author":"Zucali","year":"2021","journal-title":"Mediastinum"},{"issue":"8","key":"10.1016\/j.lungcan.2025.108554_b0030","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jtho.2019.04.015","article-title":"Molecular classification of neuroendocrine tumors of the thymus","volume":"14","author":"Dinter","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108554_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3941\/jrcr.v14i1.3737","article-title":"Primary neuroendocrine tumor of the thymus: radiological and pathological correlation","volume":"14","author":"Berman","year":"2020","journal-title":"J. Radiol. Case Rep."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108554_b0040","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jtcvs.2014.08.061","article-title":"Outcome of primary neuroendocrine tumors of the thymus: a joint analysis of the International Thymic Malignancy Interest Group and the European Society of Thoracic Surgeons databases","volume":"149","author":"Filosso","year":"2015","journal-title":"J. Thorac. Cardiovasc. Surg."},{"issue":"29","key":"10.1016\/j.lungcan.2025.108554_b0045","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000034350","article-title":"Neuroendocrine tumors in a patient with multiple endocrine neoplasia type 1 syndrome: A case report and review of the literature","volume":"102","author":"Deng","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.lungcan.2025.108554_b0050","article-title":"Current treatment approaches for thymic epithelial tumors","volume":"13","author":"Tartarone","year":"2023","journal-title":"Life (Basel)"},{"issue":"Suppl 5","key":"10.1016\/j.lungcan.2025.108554_b0055","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann. Oncol."},{"issue":"14","key":"10.1016\/j.lungcan.2025.108554_b0060","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.7150\/jca.30240","article-title":"Comparison between CT and MRI in the diagnostic accuracy of thymic masses","volume":"10","author":"Li","year":"2019","journal-title":"J. Cancer"},{"issue":"9","key":"10.1016\/j.lungcan.2025.108554_b0065","article-title":"Diagnostic utility of PET CT in thymic tumours with emphasis on 68Ga-DOTATATE PET CT in thymic neuroendocrine tumour - experience at a tertiary level hospital in India","volume":"8","author":"Hephzibah","year":"2014","journal-title":"J. Clin. Diagn. Res."},{"issue":"9 Suppl 2","key":"10.1016\/j.lungcan.2025.108554_b0070","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/JTO.0000000000000290","article-title":"The IASLC\/ITMIG thymic epithelial tumors staging project: proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors","volume":"9","author":"Detterbeck","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108554_b0075","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jtho.2023.09.002","article-title":"The international association for the study of lung cancer thymic epithelial tumors staging project: proposal for a stage classification for the forthcoming (ninth) edition of the TNM classification of malignant tumors","volume":"18","author":"Ruffini","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108554_b0080","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0003-4975(03)00555-1","article-title":"Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan","volume":"76","author":"Kondo","year":"2003","journal-title":"Annals Thorac. Surg."},{"issue":"127","key":"10.1016\/j.lungcan.2025.108554_b0085","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1183\/09059180.00007312","article-title":"Thymic epithelial tumours: from basic principles to individualised treatment strategies","volume":"22","author":"Girard","year":"2013","journal-title":"Eur. Respir. Rev."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108554_b0090","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/ejcts\/ezu277","article-title":"A meta-analysis of debulking surgery versus surgical biopsy for unresectable thymoma","volume":"47","author":"Hamaji","year":"2015","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"9","key":"10.1016\/j.lungcan.2025.108554_b0095","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.1997.15.9.3093","article-title":"Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial","volume":"15","author":"Loehrer","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108554_b0100","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00432-014-1800-6","article-title":"Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy","volume":"141","author":"Okuma","year":"2015","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108554_b0105","doi-asserted-by":"crossref","unstructured":"N. Xua, C. Wangb, Q. Zhang, et al., A phase II clinical trial of neoadjuvant concurrent chemoradiotherapy for locally advanced high-grade thymic tumors, JTO Clinical and Research Reports, 100821 2025. doi: 10.1016\/j.jtocrr.2025.100821.","DOI":"10.1016\/j.jtocrr.2025.100821"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108554_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2009.02.016","article-title":"Postoperative radiotherapy after surgical resection of thymoma: differing roles in localized and regional disease","volume":"76","author":"Forquer","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108554_b0115","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/JTO.0000000000000128","article-title":"European society of thoracic surgeons thymic working group. thymic carcinoma: a cohort study of patients from the European society of thoracic surgeons database","volume":"9","author":"Ruffini","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2025.108554_b0120","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/cncr.29166","article-title":"Japanese Association for Research on the Thymus. Postoperative radiotherapy is effective for thymic carcinoma but not for thymoma in stage II and III thymic epithelial tumors: the Japanese association for research on the thymus database study","volume":"121","author":"Omasa","year":"2015","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108554_b0125","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jtho.2023.12.011","article-title":"Postoperative radiation therapy for thymic carcinoma: an analysis of the international thymic malignancy interest group\/european society of thoracic surgeons database","volume":"19","author":"Rimner","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2025.108554_b0130","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/icvts\/ivs133","article-title":"Which stages of thymoma benefit from adjuvant chemotherapy post-thymectomy?","volume":"15","author":"Attaran","year":"2012","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108554_b0135","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.athoracsur.2019.11.009","article-title":"The role of adjuvant therapy in advanced thymic carcinoma: a national cancer database analysis","volume":"109","author":"Kim","year":"2020","journal-title":"Ann. Thorac. Surg."},{"issue":"12","key":"10.1016\/j.lungcan.2025.108554_b0140","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1097\/JTO.0b013e31822e71c0","article-title":"Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma","volume":"6","author":"Agatsuma","year":"2011","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2025.108554_b0145","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/1759-7714.12891","article-title":"Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma","volume":"10","author":"Wang","year":"2019","journal-title":"Thorac. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2025.108554_b0150","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/cncr.11606","article-title":"Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma","volume":"98","author":"Yoh","year":"2003","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.lungcan.2025.108554_b0155","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108554_b0160","doi-asserted-by":"crossref","unstructured":"C., P., G., M. S. G. Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial. Ann. Oncol., 34(Supp 2) 2023, S1337.","DOI":"10.1016\/j.annonc.2023.10.101"},{"key":"10.1016\/j.lungcan.2025.108554_b0165","doi-asserted-by":"crossref","first-page":"8110","DOI":"10.1200\/JCO.2024.42.16_suppl.8110","article-title":"S1701: A randomized phase II trial of carboplatin-paclitaxel with and without ramucirumab in patients with locally advanced, recurrent, or metastatic thymic carcinoma","volume":"42","author":"Tsao","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.lungcan.2025.108554_b0170","doi-asserted-by":"crossref","unstructured":"T. Mimori, et al., LBA8 Phase II trial of atezolizumab plus carboplatin and paclitaxel in patients with metastatic or recurrent thymic carcinoma: Marble study Ann. Oncol., 35, S1631-S1632.","DOI":"10.1016\/j.annonc.2024.10.657"},{"key":"10.1016\/j.lungcan.2025.108554_b0175","doi-asserted-by":"crossref","unstructured":"H. Shi, et al., 2188P First-line combination of toripalimab and chemotherapy in advanced thymic carcinoma: A prospective, single-arm, phase II trial. Ann. Oncol., 34, S1132-S1133.","DOI":"10.1016\/j.annonc.2023.09.970"},{"issue":"Supp 10","key":"10.1016\/j.lungcan.2025.108554_b0180","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1016\/j.jtho.2024.09.124","article-title":"MA05.03 A phase II study of tislelizumab combined with chemotherapy in patients with thymic carcinoma","volume":"19","author":"Wu","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.lungcan.2025.108554_b0185","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11154-017-9432-1","article-title":"Chemotherapy in NETs: When and how","volume":"18","author":"Angelousi","year":"2017","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108554_b0190","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.lungcan.2012.12.001","article-title":"Treatment, prognostic markers and survival in thymic neuroendocrine tumours. a study from a single tertiary referral centre","volume":"79","author":"Crona","year":"2013","journal-title":"Lung Cancer"},{"issue":"14","key":"10.1016\/j.lungcan.2025.108554_b0195","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.2217\/fon.14.144","article-title":"Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial","volume":"10","author":"Palmieri","year":"2014","journal-title":"Future Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2025.108554_b0200","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1470-2045(20)30162-5","article-title":"Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial","volume":"21","author":"Sato","year":"2020","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108554_b0205","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jtho.2020.11.003","article-title":"Durable response in patients with thymic carcinoma treated with pembrolizumab after prolonged follow-up","volume":"16","author":"Giaccone","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2025.108554_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101576","article-title":"Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial","volume":"8","author":"Girard","year":"2023","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.lungcan.2025.108554_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100419","article-title":"Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers","volume":"7","author":"Tabernero","year":"2022","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.lungcan.2025.108554_b0220","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16010166","article-title":"Molecular and functional key features and oncogenic drivers in thymic carcinomas","volume":"16","author":"Barachini","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.lungcan.2025.108554_b0225","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11102722","article-title":"Immunotherapy and targeted therapies efficacy in thymic epithelial tumors: a systematic review","volume":"11","author":"Agrafiotis","year":"2023","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.lungcan.2025.108554_b0230","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.cllc.2024.02.002","article-title":"Artemis: a multicenter, open-label, single-arm, phase ii study to evaluate the efficacy and safety of first-line carboplatin\/paclitaxel\/lenvatinib\/pembrolizumab combination for previously untreated advanced or recurrent thymic carcinomas","volume":"25","author":"Okuma","year":"2024","journal-title":"Clin. Lung Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T20:21:33Z","timestamp":1753993293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225004465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":46,"alternative-id":["S0169500225004465"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108554","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic management of patients with advanced thymic malignancies: A review for clinicians","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108554","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108554"}}